ALCOHOL, METABOLISMO Y SISTEMA INMUNE
Universitat de Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Universitat de Barcelona (40)
2023
-
Associations of hypomagnesemia in patients seeking a first treatment of alcohol use disorder
Drug and Alcohol Dependence, Vol. 245
-
Qualitative Subgenomic RNA to Monitor the Response to Remdesivir in Hospitalized Patients With Coronavirus Disease 2019: Impact on the Length of Hospital Stay and Mortality
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 1, pp. 32-38
-
Sex differences in the comorbidity of patients seeking a first treatment for Alcohol Use Disorder
International Journal of Mental Health and Addiction
2022
-
A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
Neuropsychiatric Disease and Treatment, Vol. 18, pp. 965-976
2021
-
Clinical characterization and outcomes of 85 patients with neurosarcoidosis
Scientific Reports, Vol. 11, Núm. 1
-
Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients
Joint Bone Spine, Vol. 88, Núm. 6
-
Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients
PLoS ONE, Vol. 16, Núm. 4 April
2020
-
Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease
Quality of Life Research, Vol. 29, Núm. 3, pp. 607-617
-
Corrigendum to “Evaluation of previous substance dependence genome-wide significant findings in a Spanish sample” (Drug and Alcohol Dependence (2018) 187 (358–362), (S0376871618302096), (10.1016/j.drugalcdep.2018.03.013))
Drug and Alcohol Dependence
-
Rituximab treatment for IgA vasculitis: A systematic review
Autoimmunity Reviews, Vol. 19, Núm. 4
2019
-
ADGRL3 (LPHN3) variants predict substance use disorder
Translational Psychiatry, Vol. 9, Núm. 1
-
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 579-592
-
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients
Clinical and Experimental Rheumatology, Vol. 37, pp. S97-S106
-
The Big Data Sjögren consortium: A project for a new data science era
Clinical and Experimental Rheumatology, Vol. 37, pp. S19-S23
-
The more you take it, the better it works: Six-month results of a nalmefene phase-IV trial
Journal of Clinical Medicine, Vol. 8, Núm. 4
2018
-
Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis
Journal of Infection, Vol. 76, Núm. 4, pp. 342-347
-
Evaluation of previous substance dependence genome-wide significant findings in a Spanish sample
Drug and Alcohol Dependence, Vol. 187, pp. 358-362
-
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project)
Clinical and Experimental Rheumatology, Vol. 36, pp. S102-S111
-
Reply to Braillon et al.: Nalmefene Phase IV Study: A Seeding Flying in the Face of Evidence?
Clinical Drug Investigation
-
Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results
Clinical Drug Investigation, Vol. 38, Núm. 2, pp. 147-155